Literature DB >> 17039570

Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis.

Ivo Sonderegger1, Till A Röhn, Michael O Kurrer, Giandomenica Iezzi, Yu Zou, Robert A Kastelein, Martin F Bachmann, Manfred Kopf.   

Abstract

The most common reason for heart failure in young adults is dilated cardiomyopathy often resulting from myocarditis. Clinical studies and animal models provide evidence that an autoimmune response against heart myosin is the underlying reason for the disease. IL-12 has been suggested to play a key role in development of experimental autoimmune myocarditis (EAM), as IL-12p40 and IL-12Rbeta1 knockouts are protected from disease. In this study, we have compared IL-12p40-/- mice, IL-12p35-/- mice and mice treated with a neutralizing IL-23 antibody in EAM and found that in fact IL-23, not IL-12, is responsible for inflammatory heart disease. However, these cytokines appear to have redundant activity for priming and expansion of autoreactive CD4 T cells, as specific T cell proliferation was only defective in the absence of both cytokines. IL-23 has been suggested to promote a pathogenic IL-17-producing T cell population. We targeted IL-17 by capitalizing on an active vaccination approach that effectively breaks B cell tolerance. Neutralization of IL-17 reduced myocarditis and heart autoantibody responses, suggesting that IL-17 is the critical effector cytokine responsible for EAM. Thus, targeting of IL-23 and IL-17 by passive and active vaccination strategies holds promise as a therapeutic approach to treat patients at risk for development of dilated cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17039570     DOI: 10.1002/eji.200636484

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  60 in total

Review 1.  Averting inflammation by targeting the cytokine environment.

Authors:  Manfred Kopf; Martin F Bachmann; Benjamin J Marsland
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

Review 2.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

3.  CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells.

Authors:  Giandomenica Iezzi; Ivo Sonderegger; Franziska Ampenberger; Nicole Schmitz; Benjamin J Marsland; Manfred Kopf
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-09       Impact factor: 11.205

Review 4.  Induction and regulation of pathogenic Th17 cell responses in schistosomiasis.

Authors:  Bridget M Larkin; Patrick M Smith; Holly E Ponichtera; Mara G Shainheit; Laura I Rutitzky; Miguel J Stadecker
Journal:  Semin Immunopathol       Date:  2012-10-25       Impact factor: 9.623

Review 5.  Anti-cytokine vaccines and the immunotherapy of autoimmune diseases.

Authors:  David C Wraith
Journal:  Eur J Immunol       Date:  2006-11       Impact factor: 5.532

Review 6.  IL-17RC: a partner in IL-17 signaling and beyond.

Authors:  Allen W Ho; Sarah L Gaffen
Journal:  Semin Immunopathol       Date:  2009-12-13       Impact factor: 9.623

7.  Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections.

Authors:  Jason M Brenchley; Mirko Paiardini; Kenneth S Knox; Ava I Asher; Barbara Cervasi; Tedi E Asher; Phillip Scheinberg; David A Price; Chadi A Hage; Lisa M Kholi; Alexander Khoruts; Ian Frank; James Else; Timothy Schacker; Guido Silvestri; Daniel C Douek
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

8.  Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis.

Authors:  Emma Guttman-Yassky; Michelle A Lowes; Judilyn Fuentes-Duculan; Lisa C Zaba; Irma Cardinale; Kristine E Nograles; Artemis Khatcherian; Inna Novitskaya; John A Carucci; Reuven Bergman; James G Krueger
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

9.  Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice.

Authors:  David Bending; Hugo De la Peña; Marc Veldhoen; Jenny M Phillips; Catherine Uyttenhove; Brigitta Stockinger; Anne Cooke
Journal:  J Clin Invest       Date:  2009-02-02       Impact factor: 14.808

10.  Versatile virus-like particle carrier for epitope based vaccines.

Authors:  Alain C Tissot; Regina Renhofa; Nicole Schmitz; Indulis Cielens; Edwin Meijerink; Velta Ose; Gary T Jennings; Philippe Saudan; Paul Pumpens; Martin F Bachmann
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.